within Pharmacolibrary.Drugs.ATC.V;

model V10XX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 5.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 7400 / 1000000,
    adminCount     = 1,
    Vd             = 0.06,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Lutetium (177Lu) vipivotide tetraxetan (INN; formerly known as lutetium-177 PSMA-617, trade name Pluvicto) is a radioligand therapeutic used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Administered intravenously, it delivers targeted radiation to PSMA-expressing cancer cells. It is approved for clinical use in certain advanced prostate cancers.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult male patients with PSMA-positive metastatic castration-resistant prostate cancer following intravenous administration.</p><h4>References</h4><ol><li><p>Zhang, J, et al., &amp; Baum, RP (2019). Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema. <i>Clinical nuclear medicine</i> 44(6) 501–503. DOI:<a href=&quot;https://doi.org/10.1097/RLU.0000000000002552&quot;>10.1097/RLU.0000000000002552</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30932981/&quot;>https://pubmed.ncbi.nlm.nih.gov/30932981</a></p></li><li><p>Zang, J, et al., &amp; Chen, X (2019). First-in-human study of . <i>European journal of nuclear medicine and molecular imaging</i> 46(1) 148–158. DOI:<a href=&quot;https://doi.org/10.1007/s00259-018-4096-y&quot;>10.1007/s00259-018-4096-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30090965/&quot;>https://pubmed.ncbi.nlm.nih.gov/30090965</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V10XX05;
